Developer docs
API playgroundTry for free, no card

Search company profiles

Quibim

Full company profile

uuid00008oh

Namestring
Quibim
Legal namestring
Quibim
Websiteurl
quibim.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Quibim is a Valencia, Spain-based healthtech company founded in 2012 that builds cloud-based radiomics and AI imaging biomarker solutions for precision medicine. Its core technology, the QP-Insights® platform, is a tissue-agnostic, web-based system that ingests, indexes, harmonizes, and stores large-scale medical imaging data (MRI, CT, PET/CT) and multi-omics datasets, standardizing image quality across equipment manufacturers. On top of this platform sit five regulated Software as a Medical Device products: QP-Prostate® (PI-RADS v2.1 compliant prostate MRI analysis), QP-Brain® (brain volumetry and white matter hyperintensity analysis), QP-Liver® (fat and iron quantification with automated liver segmentation), QP-Breast®, and QP-Lung®, each with FDA, CE, UKCA and (for QP-Prostate) Health Canada clearances. The company applies proprietary radiomics and deep feature extraction to support clinical research, biomarker discovery, and predictive analytics for survival, treatment response, and toxicity.

Quibim serves two distinct customer segments. Its primary commercial channel targets healthcare providers (hospitals, radiology departments, imaging centers) through direct enterprise sales and through OEM distribution partnerships with Philips (embedding QP-Prostate and QP-Brain in Philips' Advanced Visualization Workspace and BlueSeal MRI systems, with a 44% reading-time reduction cited at RSNA 2025) and with Aidoc (integrating QP-Prostate into the aiOS platform across 1,600+ hospitals). The second segment is biopharmaceutical companies, where Quibim operates value-based partnerships for patient stratification, treatment response prediction, and toxicity monitoring in clinical trials; named biopharma partners include Merck KGaA and Novartis. Revenue mechanics are quote-based, with recurring subscription-style SaMD licensing to hospitals and platform licensing to pharma. The company holds ISO 27001:2022, HIPAA and GDPR certifications and is venture-backed, having closed a $50 million Series A in January 2025 led by Asabys and Buenavista to fund US expansion, product development, and global partnerships.

Operationally, Quibim is led by co-founder and CEO Angel Alberich-Bayarri with co-founder Luis Martí Bonmatí serving as Founder and Scientific Advisor, alongside a commercial team including a CFO (Matthew Good), CSO (Kabir Mahajan), CCO (Peter Segers), and functional VPs across discovery, regulatory, business development, and customer success. The company has been expanding its ecosystem through partnerships with NVIDIA MONAI (model operationalization) and Vara (breast cancer screening AI distribution in Spain), and was selected in May 2026 as the only healthtech company for New York's strategic AI program.

Short descriptiontext

Quibim is a Valencia, Spain-based AI medical imaging company that builds the QP-Insights® cloud radiomics platform and FDA/CE/UKCA-cleared Software as a Medical Device products (QP-Prostate, QP-Brain, QP-Liver, QP-Breast, QP-Lung) for hospitals, radiology departments, and biopharmaceutical companies worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersValencia, Spain
HQ citystring
Valencia
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging AI, radiomics software, imaging biomarkers, precision medicine imaging, AI diagnostic software
Industry4 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Software Publishers5132
  • Scientific Research and Development Services5417
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Software (SaMD)
TypeSubscription Recurring
Description

Quibim commercializes FDA/CE/UKCA-cleared AI products (QP-Prostate, QP-Brain, QP-Liver) as Software as a Medical Device to healthcare providers. Revenue is generated through licensing of these diagnostic tools to hospitals and imaging centers.

quibim.ai
2Life Sciences / Biopharma Services
TypeSubscription Recurring
Description

Value-based partnerships with biopharma companies to accelerate drug development programs, including patient stratification, treatment response prediction, and toxicity monitoring using AI imaging biomarkers.

quibim.ai
3Platform Licensing
TypeLicensing Royalties
Description

Licensing of the QP-Insights® cloud platform and embedded AI models to pharmaceutical companies and research institutions for clinical studies and drug discovery applications.

fiercebiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 6 records shown
1QP-Prostate®
Description

AI solution for prostate MRI analysis that revolutionizes the prostate MRI read by facilitating radiologist work, providing precise quantitative information and PI-RADS compliance.

quibim.ai
+5 more records
Core offering1 text field

Quibim develops and commercializes cloud-based AI software as a medical device (SaMD) for quantitative medical imaging analysis. Its QP-Insights® platform extracts radiomics and deep features from MRI, CT, and PET/CT images, while disease-specific products (QP-Prostate®, QP-Brain®, QP-Liver®, QP-Breast®, QP-Lung®) provide regulatory-cleared diagnostic support to healthcare providers and biopharma partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced manual segmentation time for liver disease analysis through automated whole abdomen and liver segmentation
+2 more records
Product overview1 text field

Quibim is a healthtech company specializing in imaging biomarkers for precision medicine. The product portfolio consists of a cloud-based platform (QP-Insights®) with multiple AI-powered medical device software products: QP-Prostate® for prostate MRI analysis, QP-Brain® for brain volumetry and white matter analysis, QP-Liver® for liver disease quantification, QP-Breast® for breast cancer imaging, and QP-Lung® for lung imaging. The QP-Insights® platform serves as the foundational infrastructure that handles imaging data management, harmonization, indexing, storage, and multi-omics integration, while the individual QP products are specialized AI solutions that run on or integrate with this platform for specific disease applications in clinical and pharmaceutical settings.

Product and service6 records
1QP-Prostate®
CategoryMedical Imaging AI / Software as a Medical Device
Description

AI-powered prostate MRI analysis solution that integrates with PACS systems to provide automated PI-RADS v2.1 compliance evaluation, image quality assessment, and structured reports for prostate cancer detection. Designed for radiologists and healthcare providers performing prostate MRI reads.

2QP-Brain®
CategoryMedical Imaging AI / Software as a Medical Device
Description

Brain volumetry and white matter hyperintensity (WMH) analysis tool providing precise volume and morphometry calculations to support disease classification, progression monitoring, and neurological diagnosis. Targets radiologists and neurologists performing brain MRI analysis.

3QP-Liver®
CategoryMedical Imaging AI / Software as a Medical Device
Description

Liver disease management solution that quantifies fat and iron concentration to evaluate steatosis and iron overload, with automated whole abdomen and liver segmentation. Used by radiologists and hepatologists for liver imaging analysis.

4QP-Breast®
CategoryMedical Imaging AI / Software as a Medical Device
Description

AI-powered breast cancer imaging analysis solution in Quibim's product portfolio.

5QP-Lung®
CategoryMedical Imaging AI / Software as a Medical Device
Description

AI solution for lung imaging analysis in Quibim's product portfolio.

6QP-Insights®
CategoryCloud Platform / Radiomics Infrastructure
Description

Web-based cloud platform for managing, storing, and analyzing large-scale multi-omics data and medical images for clinical studies and research projects involving AI and radiomics. Handles imaging data harmonization, links imaging data with EHR information, and supports embedded products. Targeted at hospitals, research institutions, and biopharma companies running clinical studies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Quibim partnered with Germany's Vara to bring Europe's leading breast-cancer screening AI to Spain. This partnership expands Quibim's presence in the breast cancer diagnostics market through Vara's established screening AI technology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Partnership to operationalize medical imaging AI models through NVIDIA's MONAI framework. Quibim's AI capabilities are integrated via MONAI to help health systems scale imaging AI deployment across clinical workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Aidoc partnered with Quibim to add Prostate MRI AI capabilities to its aiOS platform. The partnership enables health systems to access Quibim's QP-Prostate solution through Aidoc's established deployment infrastructure across 1,600+ hospitals.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Quibim partnered with Koninklijke Philips N.V. to integrate AI into prostate cancer diagnostics. Philips integrates Quibim's QP-Prostate and QP-Brain AI solutions into its Advanced Visualization Workspace (AVW) and BlueSeal MRI systems. At RSNA 2025, Philips announced expanded AI partnerships including disease-specific diagnostic capabilities for prostate cancer.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Merck KGaA for AI imaging biomarker applications supporting pharmaceutical drug development programs. Quibim provides imaging analysis capabilities for patient stratification and treatment monitoring.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Novartis for AI-powered imaging analysis supporting pharmaceutical development programs. Collaboration focuses on integrating AI biomarkers into drug development workflows.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major imaging OEM offering AI-Rad Companion radiology AI suite across modalities. Competes broadly with Quibim across multi-organ AI imaging and represents the integrated-platform alternative to Quibim's modular approach.

TypeDirect peer
Description

Israel/US AI imaging vendor operating the aiOS platform deployed across 1,600+ hospitals. Both a distribution partner (hosting QP-Prostate) and a direct competitor in AI-driven radiology workflow.

TypeDirect peer
Description

India/US AI imaging company with FDA-cleared algorithms for head CT, chest X-ray, and lung nodule detection. Competes with Quibim across the same hospital radiology AI buying motion.

TypeDirect peer
Description

Belgium-based AI imaging company focused on brain MRI quantification (icobrain) for multiple sclerosis and neurodegeneration. Direct competitor to QP-Brain in neurological image analysis and runs a similar SaaS-to-radiology model.

TypeDirect peer
Description

Australia-based AI imaging vendor covering chest X-ray and CT triage/decision-support with broad modality coverage. Comparable multi-disease AI imaging portfolio and similar enterprise go-to-market.

6Nanox (Zebra Medical Vision)
TypeDirect peer
Description

Imaging AI portfolio acquired from Zebra Medical Vision, offering FDA-cleared algorithms across multiple body parts. Competes in the same AI-radiology SaaS category as Quibim's QP-* product family.

TypeDirect peer
Description

US-based AI company applying deep learning to pathology and oncology imaging (Prostate, breast). Closely comparable in AI imaging biomarkers for cancer diagnostics and biopharma partnerships.

TypeDirect peer
Description

Cloud-native AI imaging platform acquired by Tempus, offering cardiac, lung, and liver quantification. Direct overlap with QP-Insights as a cloud imaging-AI platform and with QP-Liver/QP-Lung modules.

TypeDirect peer
Description

UK-based quantitative imaging company offering LiverMultiScan and brain MRI tools. Competes head-to-head with QP-Liver and QP-Brain and shares the radiomics-to-precision-medicine positioning.

TypeBroad incumbent
Description

Global medical imaging OEM whose IntelliSpace AI / Advanced Visualization Workspace embeds Quibim's algorithms. Also a potential competitor as Philips broadens its own AI imaging portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quibim

Medical Imaging AI Softwarequibim.com

Quibim is a Valencia, Spain-based AI medical imaging company that builds the QP-Insights® cloud radiomics platform and FDA/CE/UKCA-cleared Software as a Medical Device products (QP-Prostate, QP-Brain, QP-Liver, QP-Breast, QP-Lung) for hospitals, radiology departments, and biopharmaceutical companies worldwide.

What Quibim does

Quibim is a Valencia, Spain-based healthtech company founded in 2012 that builds cloud-based radiomics and AI imaging biomarker solutions for precision medicine. Its core technology, the QP-Insights® platform, is a tissue-agnostic, web-based system that ingests, indexes, harmonizes, and stores large-scale medical imaging data (MRI, CT, PET/CT) and multi-omics datasets, standardizing image quality across equipment manufacturers. On top of this platform sit five regulated Software as a Medical Device products: QP-Prostate® (PI-RADS v2.1 compliant prostate MRI analysis), QP-Brain® (brain volumetry and white matter hyperintensity analysis), QP-Liver® (fat and iron quantification with automated liver segmentation), QP-Breast®, and QP-Lung®, each with FDA, CE, UKCA and (for QP-Prostate) Health Canada clearances. The company applies proprietary radiomics and deep feature extraction to support clinical research, biomarker discovery, and predictive analytics for survival, treatment response, and toxicity.

Quibim serves two distinct customer segments. Its primary commercial channel targets healthcare providers (hospitals, radiology departments, imaging centers) through direct enterprise sales and through OEM distribution partnerships with Philips (embedding QP-Prostate and QP-Brain in Philips' Advanced Visualization Workspace and BlueSeal MRI systems, with a 44% reading-time reduction cited at RSNA 2025) and with Aidoc (integrating QP-Prostate into the aiOS platform across 1,600+ hospitals). The second segment is biopharmaceutical companies, where Quibim operates value-based partnerships for patient stratification, treatment response prediction, and toxicity monitoring in clinical trials; named biopharma partners include Merck KGaA and Novartis. Revenue mechanics are quote-based, with recurring subscription-style SaMD licensing to hospitals and platform licensing to pharma. The company holds ISO 27001:2022, HIPAA and GDPR certifications and is venture-backed, having closed a $50 million Series A in January 2025 led by Asabys and Buenavista to fund US expansion, product development, and global partnerships.

Operationally, Quibim is led by co-founder and CEO Angel Alberich-Bayarri with co-founder Luis Martí Bonmatí serving as Founder and Scientific Advisor, alongside a commercial team including a CFO (Matthew Good), CSO (Kabir Mahajan), CCO (Peter Segers), and functional VPs across discovery, regulatory, business development, and customer success. The company has been expanding its ecosystem through partnerships with NVIDIA MONAI (model operationalization) and Vara (breast cancer screening AI distribution in Spain), and was selected in May 2026 as the only healthtech company for New York's strategic AI program.

Quibim firmographics

Firmographics
Name
Quibim
Legal name
Quibim
Website
https://quibim.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Quibim is a Valencia, Spain-based AI medical imaging company that builds the QP-Insights® cloud radiomics platform and FDA/CE/UKCA-cleared Software as a Medical Device products (QP-Prostate, QP-Brain, QP-Liver, QP-Breast, QP-Lung) for hospitals, radiology departments, and biopharmaceutical companies worldwide.
Ownership category
akta.pro rank

Quibim industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Software Publishers (5132), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Medical imaging AI
  • Radiomics software
  • Imaging biomarkers
  • Precision medicine imaging
  • AI diagnostic software

Where Quibim is headquartered

Location

Headquarters

HQ city
Valencia
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Quibim business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations, Others

Revenue model

  1. Medical Device Software (SaMD): Quibim commercializes FDA/CE/UKCA-cleared AI products (QP-Prostate, QP-Brain, QP-Liver) as Software as a Medical Device to healthcare providers. Revenue is generated through licensing of these diagnostic tools to hospitals and imaging centers.
  2. Life Sciences / Biopharma Services: Value-based partnerships with biopharma companies to accelerate drug development programs, including patient stratification, treatment response prediction, and toxicity monitoring using AI imaging biomarkers.
  3. Platform Licensing: Licensing of the QP-Insights® cloud platform and embedded AI models to pharmaceutical companies and research institutions for clinical studies and drug discovery applications.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Quibim product offering

Product offering

Core offering

Quibim develops and commercializes cloud-based AI software as a medical device (SaMD) for quantitative medical imaging analysis. Its QP-Insights® platform extracts radiomics and deep features from MRI, CT, and PET/CT images, while disease-specific products (QP-Prostate®, QP-Brain®, QP-Liver®, QP-Breast®, QP-Lung®) provide regulatory-cleared diagnostic support to healthcare providers and biopharma partners.

Product overview

Quibim is a healthtech company specializing in imaging biomarkers for precision medicine. The product portfolio consists of a cloud-based platform (QP-Insights®) with multiple AI-powered medical device software products: QP-Prostate® for prostate MRI analysis, QP-Brain® for brain volumetry and white matter analysis, QP-Liver® for liver disease quantification, QP-Breast® for breast cancer imaging, and QP-Lung® for lung imaging. The QP-Insights® platform serves as the foundational infrastructure that handles imaging data management, harmonization, indexing, storage, and multi-omics integration, while the individual QP products are specialized AI solutions that run on or integrate with this platform for specific disease applications in clinical and pharmaceutical settings.

Differentiator

Problem solved

Functional benefit

Brands

  • QP-Prostate®: AI solution for prostate MRI analysis that revolutionizes the prostate MRI read by facilitating radiologist work, providing precise quantitative information and PI-RADS compliance.
  • QP-Brain®
  • QP-Liver®
  • QP-Breast®
  • QP-Lung®
  • QP-Insights®

Products and services

  • QP-Prostate® AI-powered prostate MRI analysis solution that integrates with PACS systems to provide automated PI-RADS v2.1 compliance evaluation, image quality assessment, and structured reports for prostate cancer detection. Designed for radiologists and healthcare providers performing prostate MRI reads.
  • QP-Brain® Brain volumetry and white matter hyperintensity (WMH) analysis tool providing precise volume and morphometry calculations to support disease classification, progression monitoring, and neurological diagnosis. Targets radiologists and neurologists performing brain MRI analysis.
  • QP-Liver® Liver disease management solution that quantifies fat and iron concentration to evaluate steatosis and iron overload, with automated whole abdomen and liver segmentation. Used by radiologists and hepatologists for liver imaging analysis.
  • QP-Breast® AI-powered breast cancer imaging analysis solution in Quibim's product portfolio.
  • QP-Lung® AI solution for lung imaging analysis in Quibim's product portfolio.
  • QP-Insights® Web-based cloud platform for managing, storing, and analyzing large-scale multi-omics data and medical images for clinical studies and research projects involving AI and radiomics. Handles imaging data harmonization, links imaging data with EHR information, and supports embedded products. Targeted at hospitals, research institutions, and biopharma companies running clinical studies.

Quantifiable outcome

  • Reduced manual segmentation time for liver disease analysis through automated whole abdomen and liver segmentation
  • +2 more outcomes

Companies that use Quibim

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Quibim technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Quibim partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor, core and flagship.

  • VaraminorStrategic or Co-development Partner · 14 April 2026Quibim partnered with Germany's Vara to bring Europe's leading breast-cancer screening AI to Spain. This partnership expands Quibim's presence in the breast cancer diagnostics market through Vara's established screening AI technology.
  • NVIDIA MONAIcoreTechnology or Integration · 1 December 2025Partnership to operationalize medical imaging AI models through NVIDIA's MONAI framework. Quibim's AI capabilities are integrated via MONAI to help health systems scale imaging AI deployment across clinical workflows.
  • AidoccoreTechnology or Integration · 1 December 2025Aidoc partnered with Quibim to add Prostate MRI AI capabilities to its aiOS platform. The partnership enables health systems to access Quibim's QP-Prostate solution through Aidoc's established deployment infrastructure across 1,600+ hospitals.
  • PhilipsflagshipTechnology or Integration · 1 January 2024Quibim partnered with Koninklijke Philips N.V. to integrate AI into prostate cancer diagnostics. Philips integrates Quibim's QP-Prostate and QP-Brain AI solutions into its Advanced Visualization Workspace (AVW) and BlueSeal MRI systems. At RSNA 2025, Philips announced expanded AI partnerships including disease-specific diagnostic capabilities for prostate cancer.
  • Merck KGaAcoreStrategic or Co-development PartnerPartnership with Merck KGaA for AI imaging biomarker applications supporting pharmaceutical drug development programs. Quibim provides imaging analysis capabilities for patient stratification and treatment monitoring.
  • NovartiscoreStrategic or Co-development PartnerPartnership with Novartis for AI-powered imaging analysis supporting pharmaceutical development programs. Collaboration focuses on integrating AI biomarkers into drug development workflows.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Quibim competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers (AI-Rad Companion): Major imaging OEM offering AI-Rad Companion radiology AI suite across modalities. Competes broadly with Quibim across multi-organ AI imaging and represents the integrated-platform alternative to Quibim's modular approach.
  • Philips (IntelliSpace AI): Global medical imaging OEM whose IntelliSpace AI / Advanced Visualization Workspace embeds Quibim's algorithms. Also a potential competitor as Philips broadens its own AI imaging portfolio.

Direct peers

  • Aidoc: Israel/US AI imaging vendor operating the aiOS platform deployed across 1,600+ hospitals. Both a distribution partner (hosting QP-Prostate) and a direct competitor in AI-driven radiology workflow.
  • Qure.ai: India/US AI imaging company with FDA-cleared algorithms for head CT, chest X-ray, and lung nodule detection. Competes with Quibim across the same hospital radiology AI buying motion.
  • icometrix: Belgium-based AI imaging company focused on brain MRI quantification (icobrain) for multiple sclerosis and neurodegeneration. Direct competitor to QP-Brain in neurological image analysis and runs a similar SaaS-to-radiology model.
  • Annalise.ai: Australia-based AI imaging vendor covering chest X-ray and CT triage/decision-support with broad modality coverage. Comparable multi-disease AI imaging portfolio and similar enterprise go-to-market.
  • Nanox (Zebra Medical Vision): Imaging AI portfolio acquired from Zebra Medical Vision, offering FDA-cleared algorithms across multiple body parts. Competes in the same AI-radiology SaaS category as Quibim's QP-* product family.
  • Paige.AI: US-based AI company applying deep learning to pathology and oncology imaging (Prostate, breast). Closely comparable in AI imaging biomarkers for cancer diagnostics and biopharma partnerships.
  • Arterys (Tempus): Cloud-native AI imaging platform acquired by Tempus, offering cardiac, lung, and liver quantification. Direct overlap with QP-Insights as a cloud imaging-AI platform and with QP-Liver/QP-Lung modules.
  • Perspectum: UK-based quantitative imaging company offering LiverMultiScan and brain MRI tools. Competes head-to-head with QP-Liver and QP-Brain and shares the radiomics-to-precision-medicine positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Quibim social profiles

Digital presence

Quibim compliance and trust

Trust signal

Compliance3 records

Quibim financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quibim leadership team

Management profile

Number of profiles

Profiles15 records

Quibim funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quibim M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quibim

What does Quibim do?

Quibim develops and commercializes cloud-based AI software as a medical device (SaMD) for quantitative medical imaging analysis. Its QP-Insights® platform extracts radiomics and deep features from MRI, CT, and PET/CT images, while disease-specific products (QP-Prostate®, QP-Brain®, QP-Liver®, QP-Breast®, QP-Lung®) provide regulatory-cleared diagnostic support to healthcare providers and biopharma partners.

Is Quibim a public or private company?

Quibim is a private company. It is classified as venture growth investor backed and is currently operating.

When was Quibim founded?

Quibim was founded in 2015. It employs 101 to 250 people.

Where is Quibim based?

Quibim is headquartered in Valencia, Spain, in the Europe region.

How does Quibim make money?

Three revenue lines are on record. Medical Device Software (SaMD) is the primary driver. The others are life Sciences / Biopharma Services and platform Licensing.

Who are Quibim's main competitors?

Broad incumbents on record are Siemens Healthineers (AI-Rad Companion) and Philips (IntelliSpace AI). Direct peers are Aidoc, Qure.ai, icometrix, Annalise.ai, Nanox (Zebra Medical Vision), Paige.AI, Arterys (Tempus) and Perspectum.

Does Quibim have an API?

No public API is recorded for Quibim.

What industry is Quibim in?

Quibim's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
El FinancieroCanadá autoriza el uso de QP-Prostate, una herramienta de IA para detectar cáncer de próstataHealth Canada authorized QP-Prostate, an AI tool by Spanish firm Quibim, for radiologists to analyze MRI scans and detect prostate cancer. The version 2.4 analyzes images, locates suspicious areas, and provides quantitative data. The Canadian Cancer Society estimates 29,300 new prostate cancer cases in 2026.TechRoundStartup Of The Week: QuibimQuibim is a healthtech company using AI to convert medical imaging data into actionable insights for clinicians and researchers. Its tools are deployed at over 230 healthcare and research sites globally, supporting oncology, neurology, and immunology. The company operates offices in the US, UK, and Spain.Med-Tech InsightsQuibim launches CE and UKCA-marked QP-BreastQuibim launched QP-Breast, a CE and UKCA-marked AI tool for breast MRI that automatically detects suspected lesions. The tool integrates into hospital systems and targets screening and diagnostic use. It follows Quibim's QP Prostate tool, which has FDA clearance.El ReferenteQuibim crea IA para detectar el cáncer de mama por resonanciaQuibim launched QP-Breast, an AI tool for detecting breast cancer via MRI, in Europe and the UK after regulatory approvals. The tool highlights suspicious lesions and estimates risk, integrating into hospital systems. It is part of Quibim's certified product line, including QP-Prostate and QP-Brain.El ReferenteQuibim crea IA para detectar el cáncer de mama por resonanciaQuibim launched QP-Breast, an AI tool for detecting breast cancer via MRI, in Europe and the UK after regulatory approvals. The tool identifies suspicious lesions and integrates into hospital systems, addressing delays from scarce specialists and variable image interpretation. It is part of Quibim's broader certified product line.El ReferenteQuibim crea IA para detectar el cáncer de mama por resonanciaQuibim launched QP-Breast, an AI tool for detecting breast cancer via MRI, in Europe and the UK after regulatory approvals. The tool identifies suspicious lesions and integrates into hospital systems, addressing delays from scarce professionals and variable image interpretation. It is part of Quibim's certified product line, including QP-Prostate and QP-Brain.El ReferenteQuibim crea IA para detectar el cáncer de mama por resonanciaQuibim launched QP-Breast, an AI tool for detecting breast cancer via MRI, in Europe and the UK after regulatory approvals. The tool identifies suspicious lesions and integrates into hospital systems, addressing delays from scarce professionals and variable image interpretation. It is part of Quibim's certified product line, including QP-Prostate and QP-Brain.Market Research & Business IntelligencePrecision Cancer Imaging Market Size, Share & TrendsFuture Market Insights published a comprehensive market report projecting the global precision cancer imaging market to grow from USD 6,473.8 million in 2025 to USD 13,212.0 million by 2036, representing a CAGR of 6.7% over the forecast period, with China emerging as the fastest-growing market at 7.8% CAGR. The report identifies a structural shift from hardware-centric imaging to AI-software-defined platforms, noting that AI-powered tumor detection software carries gross margins above 70% compared to 25-35% for imaging hardware. Key recent developments include Philips securing EUR 23.9 million through the PreciseOnco consortium, NHS implementing a blood-test-first liquid biopsy approach for suspected lung cancer, and Quibim launching its QP-Prostate AI ecosystem at RSNA 2025.AuntMinnieAidoc partners with Nvidia MONAI, Quibim for in-house imaging modelsAidoc announced partnerships with Nvidia MONAI and Quibim at RSNA 2025 to facilitate the deployment of in-house medical imaging AI models into clinical workflows. The collaboration with Nvidia enables 'homegrown' MONAI-based models to connect directly to Aidoc's aiOS platform via a dedicated API, streamlining integration. Additionally, Aidoc and Quibim introduced QP-Prostate, an AI solution for prostate MRI analysis that evaluates image quality and identifies suspicious regions for cancer.QuibimQuibim Unveils Next-Generation Oncology Ecosystem Platform at RSNA 2025Quibim launched its next-generation oncology ecosystem platform, featuring an enhanced QP-Prostate solution with advanced 3D visualization and AI analytics, at the RSNA 2025 Annual Meeting. The company also announced a strategic partnership with Ferrum Health to facilitate the secure deployment of its AI solutions within large health systems.